Top Markets
#1 Velas Velas +367.75%
#2 Gravity Gravity +48.56%
#3 Galxe Galxe +34.81%
#4 Derive Derive +31.62%
#5 Infinity Ground Infinity Ground +29.43%
#6 Wiki Cat Wiki Cat +23.41%
#7 Audiera Audiera +22.88%
#8 Fetch.ai Fetch.ai +22.43%
#9 Fuzzybear Fuzzybear +21.78%
#10 Wrapped QUIL Wrapped QUIL +21.00%
Coin of the day
Velas Velas
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Classement en actions #20716
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel... MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.
Prix de l'action
$0.00001
Capitalisation boursière
$50.01K
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange MultiCell Technologies, Inc. (MCET)

Catégorie

Healthcare
Capitalisation boursière
Revenus
plus
Bénéfices
Historique des prix
Ratio P/E
Ratio P/S
Ratio P/B
Marge opérationnelle
EPS
Fractionnements d’actions
Dividendes
Rendement du dividende
Actions en circulation
Revenus pour MultiCell Technologies, Inc. (MCET)
Revenus en Aug 2015 TTM : $805.24
Selon les derniers rapports financiers de MultiCell Technologies, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $805.24. En 2013, l'entreprise a réalisé un chiffre d'affaires de $49.32 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour MultiCell Technologies, Inc. de 2013 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) $805.24 1,532.68%
2014 $49.32 0.00%
2013 $49.32 0.00%
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 6,015,189,493.19%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 1,495,015,026.00%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 1,781,204,416.44%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 1,127,901,460.00%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 1,949,147,196.44%
AU